{"id":"placebo-for-niraparib","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1094636","moleculeType":"Small molecule","molecularWeight":"320.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. It allows researchers to distinguish between the therapeutic effects of the actual drug and effects attributable to patient expectation, natural disease progression, or other non-pharmacological factors. In this context, it serves as the control arm in a Phase 3 trial for Niraparib, a PARP inhibitor.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:16.595Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trial for Niraparib"}]},"trialDetails":[{"nctId":"NCT04497844","phase":"PHASE3","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-23","conditions":"Metastatic Castration-sensitive Prostate Cancer","enrollment":696},{"nctId":"NCT03748641","phase":"PHASE3","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-01-25","conditions":"Castration-Resistant Prostatic Cancer","enrollment":765},{"nctId":"NCT04475939","phase":"PHASE3","title":"Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2020-10-26","conditions":"Lung Cancer, Non-Small Cell","enrollment":666},{"nctId":"NCT03602859","phase":"PHASE3","title":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","startDate":"2018-10-11","conditions":"Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma","enrollment":1400},{"nctId":"NCT03705156","phase":"PHASE3","title":"Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient","status":"UNKNOWN","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2017-06-08","conditions":"Platinum-sensitive Relapsed Ovarian Cancer","enrollment":265},{"nctId":"NCT03709316","phase":"PHASE3","title":"A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer","status":"UNKNOWN","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2018-06-30","conditions":"Ovarian Cancer","enrollment":384}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":82,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Niraparib","genericName":"Placebo for Niraparib","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 clinical trial for Niraparib.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}